<DOC>
	<DOCNO>NCT01986907</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ranibizumab patient affect wet age relate macular degeneration ( wAMD ) .</brief_summary>
	<brief_title>Safety Tolerability Ranibizumab Mono/Bilateral w-AMD Patients Eyes With BCVA &lt; 2/10 and/or 2nd Affected Eye</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Angiogenesis Modulating Agents</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 50 year Willing capable provide inform write consent Eye ( ) eligible ranibizumab treatment , BCVA 2/10 due wet AMD and/or Second eye eligible ranibizumab treatment , first eye treat ( currently previously ) ranibizumab , whichever BCVA . In bilateral wAMD patient , second eye include first eye treat least 14 day ranibizumab Active intraocular inflammation ( grade trace ) either eye Any ocular periocular active infection ( current suspect ) , e.g . conjunctivitis , keratitis , scleritis , uveitis , endophtalmitis , either eye Risk factor retinal pigment epithelial tear ( include pigment epithelial retinal detachment ) Ocular disorder may confound interpretation result compromise visual acuity require medical surgical intervention study period include cataract , retinal vascular occlusion , retinal detachment macular hole Uncontrolled glaucoma either eye ( IOP â‰¥ 30 mmHg medication accord investigator 's judgment ) History vitrectomy study eye History stroke transient ischemic attack Systemic treatment VEGF inhibitor 90 day prior study enrollment Ocular treatment study eye antiangiogenic drug within 1 month prior study enrollment Any intraocular surgery study eye within 28 day prior enrollment Women childbearing potential UNLESS use effective contraception treatment Pregnant lactate woman Simultaneous participation study include administration investigational drug Known hypersensitivity ranibizumab component ranibizumab formulation Inability comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>wet AMD</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>mono-bilateral</keyword>
	<keyword>poor visual acuity</keyword>
	<keyword>retinal disease</keyword>
	<keyword>eye disease</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>Angiogenesis Modulating Agents</keyword>
</DOC>